{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG003","value":"6"}]}],"title":"QTCB Interval 450<=Value<480"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"1"}]}],"title":"QTCB Interval 480<=Value<500"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"5"}]}],"title":"QTCF Interval 450<=Value<480"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"44"}],"units":"Participants"}],"description":"Electrocardiogram assessment included QT interval corrected using Fridericia's formula (QTcF), QT interval corrected using Bazett's formula (QTcB), both had following categories: 450\\<=Value\\<480 millisecond (msec), 480\\<=Value\\<500 msec and Value\\>=500 msec.","groups":[{"description":"Participants received placebo matched to tanezumab SC once every 8 weeks for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants in this discontinued treatment arm, received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and completed their treatment before the amendment.","id":"OG001","title":"Tanezumab 10 mg"},{"description":"Participants in this treatment group had received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and after the amendment they continued remaining treatment with tanezumab 20 mg SC once every 8 weeks.","id":"OG002","title":"Tanezumab 10/20 mg"},{"description":"Participants received tanezumab 20 mg SC once every 8 weeks for 24 weeks.","id":"OG003","title":"Tanezumab 20 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies number of participants with post-baseline results evaluated against criteria. In reporting arm \"Tanezumab10/20 mg\", the participant did not have post-baseline results evaluated against ECG (QTC) criteria, hence was not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1, before dosing) up to Week 24","title":"Number of Participants With Categorical Summary of Electrocardiogram (ECG) (QTC) Data","type":"SECONDARY","unitOfMeasure":"Participants"}